Chief Scientific Officer
Dr. Raghava has over 20 years of experience working in Academia and Pharmaceutical industry. His career started as Alexander von Humboldt (AvH) fellow at Karlsruhe Institute of Technology (KIT), Germany after completing PhD in Organic Chemistry from North Eastern Hill University (NEHU), Shillong, India in 1995. Since 1999 he has held various senior positions in pharmaceutical industry in Gemany and India and worked on several integrated drug discovery projects with various large-/mid-sized pharmas along with small biotech and virtual companies and has taken compounds from target to clinic and delivered several optimized leads across diverse therapeutic areas viz., Oncology, Pain & CNS and MD. Presently, one of his compounds ASN-001 (formerly EN3356) is in Phase I & II clinical trials (NCT 02349139) for the treatment of Metastatic Castrate Resistant Prostate Cancer (MCRPC).
To date Dr. Raghava has published over 50 research publications, patents, and invited review articles, book chapters. He is a member of several active chemical societies and reviewer of peer reviewed journals and committees.
Dr. Raghava joins LALS from Jubilant Biosys., Bangalore, where he served as Director & Head of Medicinal Chemistry, responsible for all the department scientific and operational functions.